Comparative pharmacokinetics and pharmacodynamics of cardiac glycosides.
1 The pharmacokinetics and pharmacodynamics of ouabain, digoxinn and beta-methyl digoxin (medigoxin) have been investigated in a crossover study in four normal healthy volunteers. 2 Pharmacokinetics were studied using [3H]-labelled glycosides and the shortening of the left ventricular ejection time (LVET) was used as a measure of the effect of the drugs. A graded exercise protocol was used to correct for the effects of heart rate on LVET. 3 In three of the four subjects, both digoxin and beta-methyl digoxin produced a shortening in the LVET, but no such change could be detected with ouabain in any of the four subjects. 4 There was a good linear correlation between the shortening of the LVET and the amounts of digoxin or beta-methyl digoxin present in the body tissues. 5 One subject who showed no drug-related LVET shortening had greatly enhanced clearances of all three drugs studied.
D000328:Adult; D002301:Cardiac Glycosides / Q000378:metabolism* / Q000494:pharmacology; D004077:Digoxin / Q000378:metabolism; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008297:Male; D008520:Medigoxin / Q000378:metabolism; D010042:Ouabain / Q000378:metabolism
D002301:Cardiac Glycosides; D010042:Ouabain; D004077:Digoxin; D008520:Medigoxin